Levetiracetam: A comprehensive review

Amy Z. Crepeau, David M. Treiman

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small uncontrolled studies and case series as an off-label treatment for status epilepticus, for nonepileptic neurological conditions, such as movement disorders, neuropathic pain and headaches, and for some psychiatric conditions. It has not been approved for any indication other than chronic epilepsy. A significant factor in using levetiracetam for seizures and other disorders has been its ease of dosing and tolerability. In this article, we outline how levetiracetam was discovered, the animal and human data showing its antiepileptic activity, its potential use in other neurological conditions and the significant adverse events. We also discuss the direction antiepileptic drug development will take in the future.

Original languageEnglish (US)
Pages (from-to)159-171
Number of pages13
JournalExpert Review of Neurotherapeutics
Volume10
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

etiracetam
Anticonvulsants
Epilepsy
Status Epilepticus
Movement Disorders
Neuralgia
Headache
Psychiatry

Keywords

  • Anticonvulsant
  • Antiepileptic drug
  • Epilepsy
  • Keppra®
  • Kindling model
  • Levetiracetam
  • Pyrrolidine
  • Seizure
  • Status epilepticus
  • Synaptic vesicle protein 2a

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Levetiracetam : A comprehensive review. / Crepeau, Amy Z.; Treiman, David M.

In: Expert Review of Neurotherapeutics, Vol. 10, No. 2, 02.2010, p. 159-171.

Research output: Contribution to journalArticle

Crepeau, Amy Z. ; Treiman, David M. / Levetiracetam : A comprehensive review. In: Expert Review of Neurotherapeutics. 2010 ; Vol. 10, No. 2. pp. 159-171.
@article{dba20c5bcaee466f9788d3c865728277,
title = "Levetiracetam: A comprehensive review",
abstract = "Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small uncontrolled studies and case series as an off-label treatment for status epilepticus, for nonepileptic neurological conditions, such as movement disorders, neuropathic pain and headaches, and for some psychiatric conditions. It has not been approved for any indication other than chronic epilepsy. A significant factor in using levetiracetam for seizures and other disorders has been its ease of dosing and tolerability. In this article, we outline how levetiracetam was discovered, the animal and human data showing its antiepileptic activity, its potential use in other neurological conditions and the significant adverse events. We also discuss the direction antiepileptic drug development will take in the future.",
keywords = "Anticonvulsant, Antiepileptic drug, Epilepsy, Keppra{\circledR}, Kindling model, Levetiracetam, Pyrrolidine, Seizure, Status epilepticus, Synaptic vesicle protein 2a",
author = "Crepeau, {Amy Z.} and Treiman, {David M.}",
year = "2010",
month = "2",
doi = "10.1586/ern.10.3",
language = "English (US)",
volume = "10",
pages = "159--171",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Levetiracetam

T2 - A comprehensive review

AU - Crepeau, Amy Z.

AU - Treiman, David M.

PY - 2010/2

Y1 - 2010/2

N2 - Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small uncontrolled studies and case series as an off-label treatment for status epilepticus, for nonepileptic neurological conditions, such as movement disorders, neuropathic pain and headaches, and for some psychiatric conditions. It has not been approved for any indication other than chronic epilepsy. A significant factor in using levetiracetam for seizures and other disorders has been its ease of dosing and tolerability. In this article, we outline how levetiracetam was discovered, the animal and human data showing its antiepileptic activity, its potential use in other neurological conditions and the significant adverse events. We also discuss the direction antiepileptic drug development will take in the future.

AB - Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small uncontrolled studies and case series as an off-label treatment for status epilepticus, for nonepileptic neurological conditions, such as movement disorders, neuropathic pain and headaches, and for some psychiatric conditions. It has not been approved for any indication other than chronic epilepsy. A significant factor in using levetiracetam for seizures and other disorders has been its ease of dosing and tolerability. In this article, we outline how levetiracetam was discovered, the animal and human data showing its antiepileptic activity, its potential use in other neurological conditions and the significant adverse events. We also discuss the direction antiepileptic drug development will take in the future.

KW - Anticonvulsant

KW - Antiepileptic drug

KW - Epilepsy

KW - Keppra®

KW - Kindling model

KW - Levetiracetam

KW - Pyrrolidine

KW - Seizure

KW - Status epilepticus

KW - Synaptic vesicle protein 2a

UR - http://www.scopus.com/inward/record.url?scp=76249093525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249093525&partnerID=8YFLogxK

U2 - 10.1586/ern.10.3

DO - 10.1586/ern.10.3

M3 - Article

AN - SCOPUS:76249093525

VL - 10

SP - 159

EP - 171

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 2

ER -